Press release
Gastric Cancer Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Eli Lilly and Company, BeiGene, Hutchison MediPharma, Astellas Pharma, Henlix
"Gastric Cancer Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gastric Cancer Market.
The Gastric Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Gastric Cancer Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Gastric Cancer treatment therapies with a considerable amount of success over the years.
*
Gastric Cancer companies working in the treatment market are Hubro Therapeutics, Cello Therapeutics, Idience, Leap Therapeutics, Eli Lilly and Company, BeiGene, Hutchison MediPharma, Astellas Pharma, Henlix Biotech, Jiangsu Hengrui Medicine, Neovii Biotech, Genmab/Janssen Biotech, Rapa Therapeutics LLC, HiberCell, Inc., and others, are developing therapies for the Gastric Cancer treatment
*
Emerging Gastric Cancer therapies in the different phases of clinical trials are- FMPV-1, CE008, Venadaparib, DKN-01, Abemaciclib, Tislelizumab, Fruquintinib, Zolbetuximab, HLX10, Camrelizumab, Catumaxomab, Amivantamab, RAPA-201, HC 5404 FU, and others are expected to have a significant impact on the Gastric Cancer market in the coming years.
*
In March 2025, The FDA awarded orphan drug designation to HLX22, a novel anti-HER2 monoclonal antibody, for the treatment of gastric cancer. This status offers multiple development incentives, such as tax credits for clinical trial expenses, exemption from new drug application fees, and seven years of market exclusivity once approved. These advantages are designed to speed up the development and availability of HLX22, helping patients-especially those with HER2-positive metastatic gastric (GI) or gastroesophageal junction (GEJ) cancer-gain earlier access to this therapy.
*
In February 2025, Hanmi Pharmaceutical, based in South Korea, announced favorable results from a Phase I/II clinical trial evaluating Tivumecirnon in combination with MSD's Keytruda (pembrolizumab) for patients with advanced or metastatic gastric cancer. The study was conducted in collaboration with MSD and RAPT Therapeutics. Tivumecirnon's development has been a joint effort, with RAPT Therapeutics licensing it to Hanmi in 2019, followed by a clinical collaboration agreement with MSD in 2020.
Gastric Cancer Overview
Gastric cancer, also known as stomach cancer, is a diverse illness that necessitates ongoing study and care in the areas of early detection, prevention, and cutting-edge treatment alternatives. The global distribution of GC varies significantly between geographical regions, demonstrating the wide range of factors that affect the disease's incidence, survival, and death.
Get a Free Sample PDF Report to know more about Gastric Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/gastric-cancer-pipeline-insight [https://www.delveinsight.com/report-store/gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Gastric Cancer Drugs Under Different Phases of Clinical Development Include:
*
FMPV-1: Hubro Therapeutics
*
CE008: Cello Therapeutics
*
Venadaparib: Idience
*
DKN-01: Leap Therapeutics
*
Abemaciclib: Eli Lilly and Company
*
Tislelizumab : BeiGene
*
Fruquintinib: Hutchison MediPharma
*
Zolbetuximab: Astellas Pharma
*
HLX10: Henlix Biotech
*
Camrelizumab: Jiangsu Hengrui Medicine
*
Catumaxomab: Neovii Biotech
*
Amivantamab: Genmab/Janssen Biotech
*
RAPA-201: Rapa Therapeutics LLC
*
HC 5404 FU: HiberCell, Inc.
Gastric Cancer Route of Administration
Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Gastric Cancer Molecule Type
Gastric Cancer Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Gastric Cancer Pipeline Therapeutics Assessment
*
Gastric Cancer Assessment by Product Type
*
Gastric Cancer By Stage and Product Type
*
Gastric Cancer Assessment by Route of Administration
*
Gastric Cancer By Stage and Route of Administration
*
Gastric Cancer Assessment by Molecule Type
*
Gastric Cancer by Stage and Molecule Type
DelveInsight's Gastric Cancer Report covers around 230+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Gastric Cancer product details are provided in the report. Download the Gastric Cancer pipeline report to learn more about the emerging Gastric Cancer therapies [https://www.delveinsight.com/sample-request/gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Gastric Cancer Therapeutics Market include:
Key companies developing therapies for Gastric Cancer are - EMD Serono, Sumitomo Pharma, LintonPharm Co., Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Janssen Pharmaceutical K.K., Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech,Eisai Inc., AB Science, Maxinovel Pharmaceuticals, Shanghai Miracogen Inc., GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp, and others.
Gastric Cancer Pipeline Analysis:
The Gastric Cancer pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Gastric Cancer with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastric Cancer Treatment.
*
Gastric Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Gastric Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastric Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Gastric Cancer drugs and therapies [https://www.delveinsight.com/sample-request/gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Gastric Cancer Pipeline Market Drivers
*
Increase in the number of patients suffering from Gastric Cancer, increasing awareness about the disease are some of the important factors that are fueling the Gastric Cancer Market.
Gastric Cancer Pipeline Market Barriers
*
However, late diagnosis of the Disease, lengthier treatment duration and other factors are creating obstacles in the Gastric Cancer Market growth.
Scope of Gastric Cancer Pipeline Drug Insight
*
Coverage: Global
*
Key Gastric Cancer Companies: Hubro Therapeutics, Cello Therapeutics, Idience, Leap Therapeutics, Eli Lilly and Company, BeiGene, Hutchison MediPharma, Astellas Pharma, Henlix Biotech, Jiangsu Hengrui Medicine, Neovii Biotech, Genmab/Janssen Biotech, Rapa Therapeutics LLC, HiberCell, Inc., and others
*
Key Gastric Cancer Therapies: FMPV-1, CE008, Venadaparib, DKN-01, Abemaciclib, Tislelizumab, Fruquintinib, Zolbetuximab, HLX10, Camrelizumab, Catumaxomab, Amivantamab, RAPA-201, HC 5404 FU, and others
*
Gastric Cancer Therapeutic Assessment: Gastric Cancer current marketed and Gastric Cancer emerging therapies
*
Gastric Cancer Market Dynamics: Gastric Cancer market drivers and Gastric Cancer market barriers
Request for Sample PDF Report for Gastric Cancer Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Gastric Cancer Report Introduction
2. Gastric Cancer Executive Summary
3. Gastric Cancer Overview
4. Gastric Cancer- Analytical Perspective In-depth Commercial Assessment
5. Gastric Cancer Pipeline Therapeutics
6. Gastric Cancer Late Stage Products (Phase II/III)
7. Gastric Cancer Mid Stage Products (Phase II)
8. Gastric Cancer Early Stage Products (Phase I)
9. Gastric Cancer Preclinical Stage Products
10. Gastric Cancer Therapeutics Assessment
11. Gastric Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Gastric Cancer Key Companies
14. Gastric Cancer Key Products
15. Gastric Cancer Unmet Needs
16 . Gastric Cancer Market Drivers and Barriers
17. Gastric Cancer Future Perspectives and Conclusion
18. Gastric Cancer Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=gastric-cancer-pipeline-2025-latest-fda-approvals-clinical-trials-and-emerging-therapies-assessment-by-delveinsight-eli-lilly-and-company-beigene-hutchison-medipharma-astellas-pharma-henlix]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gastric Cancer Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Eli Lilly and Company, BeiGene, Hutchison MediPharma, Astellas Pharma, Henlix here
News-ID: 4168595 • Views: …
More Releases from ABNewswire
Pegasus Angel Accelerator Unlocks $1M+ in Perks & Tools for Founders
Over 100 exclusive offers - and growing - designed to help startups save money, move fast, and build smarter.
SANTA MONICA - September 3, 2025 - Pegasus Angel Accelerator [https://www.pegasusangelaccelerator.com/?utm_source=pr&utm_medium=google&utm_campaign=ABNews] today announced its official Startup Perks & Partner Benefits, giving founders lifetime access to more than $1M in free and discounted tools, credits, and services. With over 100 perks already live - and new ones being added every week - Pegasus…
Web 907 Sets New Standard: Baseline SEO Now Included with Every Website
Web 907 Now Includes Baseline SEO with Every New Website. Fairbanks-based web design company Web 907 announced it will now include its Baseline SEO Package with all new websites at no extra cost. This change is in response to the rise of AI-powered search tools and overviews. The package includes Google Analytics, Search Console setup, on-page SEO, and sitemap installation - helping businesses stay visible in a changing SEO landscape.…
AV Access Launches BizEye 90: A 4K AI Webcam with Wide-Angle View and Intelligen …
AV Access unveils the BizEye 90, a compact 4K AI webcam with a 120 degrees wide-angle lens, intelligent framing, and dual noise-canceling mics-ideal for hybrid meetings and remote collaboration. It works seamlessly with the eShare W90 wireless presentation and conferencing system to deliver a plug-and-play video conferencing experience.
AV Access, a leading provider of Pro AV and AV over IP solutions, continues to expand its hybrid conferencing portfolio with the launch…
Spinal Cord Injury Pipeline 2025: Comprehensive Clinical Trials and Therapies An …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinal Cord Injury pipeline constitutes 25+ key companies continuously working towards developing 30+ Spinal Cord Injury treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinal Cord Injury Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/spinal-cord-injury-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinal Cord Injury Market.
The…
More Releases for Gastric
Increasing Geriatric Population Fuels Gastric Ulcers Market Growth Driving Marke …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Gastric Ulcers Market Size By 2025?
In the last few years, the market size for gastric ulcers has been expanding notably. It is anticipated to increase from $4.29 billion in 2024 to $4.54 billion in 2025, boasting a compound annual growth rate (CAGR) of 5.9%.…
Increasing Geriatric Population Fuels Gastric Ulcers Market Growth Driver: Leadi …
How Are the key drivers contributing to the expansion of the gastric ulcers market?
The rising geriatric population is expected to accelerate the growth of the gastric ulcers market. The geriatric population, typically individuals aged 65 and above, is growing due to improvements in healthcare and increased life expectancy. This population is more susceptible to gastric ulcers due to factors like the use of NSAIDs and decreased mucosal protection. For instance,…
Top Factor Driving Gastric Cancer Drugs Market Growth in 2025: Rising Gastric Ca …
What market dynamics are playing a key role in accelerating the growth of the gastric cancer drugs market?
The rise in obesity and smoking rates has led to an increased prevalence of gastric cancer. Factors like tobacco use and poor dietary habits have been linked to a higher risk of developing this disease. As per data from the Government Digital Service in the UK, it was projected in May 2023 that…
Gastric Cancer Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Gastric Cancer Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including Gastric Cancer clinical trials and nonclinical stage products. It also covers the Gastric Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Gastric Cancer…
Gastric Function Test Market - Empowering Digestive Health: Gastric Function Tes …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Gastric Function Test Market.
Gastric Function Test Market: https://www.growthplusreports.com/report/gastric-function-test-market/9126
The Gastric Function Test Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the…
The Virtual Gastric Band 101
There’s been a lot in the media recently about the Hypnotic Gastric Band or also known as The Virtual Gastric Band. I get asked a lot about it so thought I’d give a Virtual Gastric Band 101 on what it is, but more importantly what it’s not.
The Virtual Gastric Band - It is a non-surgical technique which uses the power of hypnosis to retrain the person to be satisfied with smaller…
